Literature DB >> 22385025

Dyspnea in palliative care: expanding the role of corticosteroids.

Richard J Lin1, Ronald D Adelman, Sonal S Mehta.   

Abstract

Dyspnea is one of the most common symptoms in advanced cancer patients at the end of their life. It is often multifactorial with diverse malignant, nonmalignant, and cancer treatment related etiologies. Oxygen, opiates, and anxiolytics are commonly administered. Here a complex case of progressive dyspnea and its treatments in a patient with advanced pancreatic cancer is described, and its multiple potential contributing causes are identified and clinical responses evaluated. Literature review is conducted on pulmonary drug toxicity and tumor lymphangitic spread, and the role of corticosteroids in relieving dyspnea in the palliative care setting.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22385025      PMCID： PMC7001421          DOI： 10.1089/jpm.2011.0260

Source DB:  PubMed          Journal:  J Palliat Med        ISSN： 1557-7740            Impact factor:   2.947


  20 in total

Review 1.  Diagnostic approach to the patient with diffuse lung disease.

Authors:  Jay H Ryu; Eric J Olson; David E Midthun; Stephen J Swensen
Journal:  Mayo Clin Proc       Date:  2002-11       Impact factor: 7.616

Review 2.  Role of corticosteroids in palliative care.

Authors:  Allen Shih; Kenneth C Jackson
Journal:  J Pain Palliat Care Pharmacother       Date:  2007

3.  High-dose corticosteroids for the management of dyspnea in patients with tumor obstruction of the upper airway.

Authors:  Ahmed Elsayem; Eduardo Bruera
Journal:  Support Care Cancer       Date:  2007-07-17       Impact factor: 3.603

Review 4.  Amiodarone-induced pulmonary toxicity: an under-recognized and severe adverse effect?

Authors:  Martin Schwaiblmair; Thomas Berghaus; Thomas Haeckel; Theodor Wagner; Wolfgang von Scheidt
Journal:  Clin Res Cardiol       Date:  2010-07-10       Impact factor: 5.460

Review 5.  Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus.

Authors:  N P Rowell; F V Gleeson
Journal:  Cochrane Database Syst Rev       Date:  2001

6.  A prospective survey of the use of dexamethasone on a palliative care unit.

Authors:  J R Hardy; E Rees; J Ling; R Burman; D Feuer; K Broadley; P Stone
Journal:  Palliat Med       Date:  2001-01       Impact factor: 4.762

Review 7.  Squamous cell carcinoma of the cervix presenting as lymphangitic carcinomatosis: a case report and review of the literature.

Authors:  Kristina Storck; Marta Crispens; Kevin Brader
Journal:  Gynecol Oncol       Date:  2004-09       Impact factor: 5.482

Review 8.  Management of dyspnea.

Authors:  Jay R Thomas; Charles F von Gunten
Journal:  J Support Oncol       Date:  2003 May-Jun

9.  Dyspnea in the advanced cancer patient.

Authors:  D J Dudgeon; M Lertzman
Journal:  J Pain Symptom Manage       Date:  1998-10       Impact factor: 3.612

Review 10.  Pulmonary complications of novel antineoplastic agents for solid tumors.

Authors:  Bobbak Vahid; Paul E Marik
Journal:  Chest       Date:  2008-02       Impact factor: 9.410
View more
  9 in total

Review 1.  Do Patients Benefit from a Trial of Corticosteroids at the End of Life?

Authors:  Sriram Yennurajalingam; Eduardo Bruera
Journal:  Curr Treat Options Oncol       Date:  2022-04-01

2.  Dexamethasone for Dyspnea in Cancer Patients: A Pilot Double-Blind, Randomized, Controlled Trial.

Authors:  David Hui; Kelly Kilgore; Susan Frisbee-Hume; Minjeong Park; Anne Tsao; Marvin Delgado Guay; Charles Lu; William William; Katherine Pisters; George Eapen; Frank Fossella; Sapna Amin; Eduardo Bruera
Journal:  J Pain Symptom Manage       Date:  2016-06-18       Impact factor: 3.612

Review 3.  Exploring the immune-checkpoint inhibitors' efficacy/tolerability in special non-small cell lung cancer (NSCLC) populations: focus on steroids and autoimmune disease.

Authors:  Francesco Passiglia; Valeria Cetoretta; Marco De Filippis; Valerio Napoli; Silvia Novello
Journal:  Transl Lung Cancer Res       Date:  2021-06

4.  Systemic corticosteroids for the management of cancer-related breathlessness (dyspnoea) in adults.

Authors:  Alison Haywood; Jacqueline Duc; Phillip Good; Sohil Khan; Kirsty Rickett; Petra Vayne-Bossert; Janet R Hardy
Journal:  Cochrane Database Syst Rev       Date:  2019-02-20

5.  Metastatic pancreatic carcinoma masquerading as cystic lung disease: a rare presentation.

Authors:  Emily Stern; Taha Huseini; YiJin Kuok; Fiona Lake
Journal:  Respirol Case Rep       Date:  2017-06-11

Review 6.  Unanswered questions and future direction in the management of terminal breathlessness in patients with cancer.

Authors:  Masanori Mori; Takashi Yamaguchi; Yoshinobu Matsuda; Kozue Suzuki; Hiroaki Watanabe; Ryo Matsunuma; Jun Kako; Kengo Imai; Yuko Usui; Yoshihisa Matsumoto; David Hui; David Currow; Tatsuya Morita
Journal:  ESMO Open       Date:  2020-09-30

7.  [Progress of Steroids Effect on Efficacy of Immune Checkpoint Inhibitors].

Authors:  Guoqiang Pan; Yun Fan
Journal:  Zhongguo Fei Ai Za Zhi       Date:  2019-12-20

Review 8.  Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era.

Authors:  Laura Kalfeist; Loïck Galland; Fanny Ledys; François Ghiringhelli; Emeric Limagne; Sylvain Ladoire
Journal:  Cells       Date:  2022-02-22       Impact factor: 6.600

9.  Effect of Systemic Corticosteroid Therapy on the Efficacy and Safety of Nivolumab in the Treatment of Non-Small-Cell Lung Cancer.

Authors:  Kengo Umehara; Kaori Yama; Keisuke Goto; Azusa Wakamoto; Tae Hatsuyama; Osamu Honjo; Toyohiro Saikai; Akihisa Fujita; Hideki Sato
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.